Novakand Pharma AB (publ) (LARK) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.029x

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has a cash flow conversion efficiency ratio of -0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.64 Million ≈ $-176.17K USD) by net assets (Skr55.49 Million ≈ $5.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Novakand Pharma AB (publ) (LARK) stock price for real-time trading data and today's change.

Novakand Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Novakand Pharma AB (publ) stock valuation for the company's overall valuation and market capitalisation.

Novakand Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Novakand Pharma AB (publ) ranked by their cash flow conversion efficiency. Also see Novakand Pharma AB (publ) asset portfolio for a full breakdown of the balance sheet.

Company	Cash Flow Conversion Efficiency
Enthusiast Gaming Holdings Inc TO:EGLX	1.951x
Co-Diagnostics, Inc. Common Stock NASDAQ:CODX	-0.489x
Carmell Therapeutics Corporation NASDAQ:CTCX	0.198x
Ta Win Holdings Bhd KLSE:7097	-0.034x
Fancy Wood Industries Public Company Limited BK:FANCY	0.011x
Dunedin Income Growth Investment Trust PLC LSE:DIG	0.016x
DSS Inc NYSE MKT:DSS	-0.290x
Golden Tobacco Limited NSE:GOLDENTOBC	0.032x

Annual Cash Flow Conversion Efficiency for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Novakand Pharma AB (publ) from 2012 to 2025. Review Novakand Pharma AB (publ) leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr55.49 Million ≈ $5.97 Million	Skr-12.78 Million ≈ $-1.38 Million	-0.230x	+44.96%
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.60 Million

Skr42.77 Million SEK

Market Cap Rank

#28827 Global

#5877 in USA

Share Price

Skr2.16

Change (1 day)

-0.92%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56